There is an investor presentation slide show in this link that is worth watching. Very strong marketing team. https://seekingalpha.com/article/44...o-invitations-xi-virtual-conference-slideshow
Hmmmmm. I think its gonna depend on what they say going forward. Also, is this stock going to start behaving like NFLX has in the past.... ie, new "subscribers", in this case it would be new accounts I guess. Reason I say that Stoney.... these kids under 30, man I bet they are all getting accounts where its legal. So for tomorrow's earnings report, revenue growth will obviously be important, but I suspect the Street will be eyeing new account growth. It's priced to perfection Stoney.... I dunno. Depending on how many shares you bought, you might wanna buy a couple $48 puts at $0.90 here. If it goes to $57, you miss out on $0.90 of $10/share profit. No biggie. I don't think it'll go to $57 though Stoney. Those options would be way more pricey.
EVFM, been dead money for months. Still holding $.77 because hope works so well in investing. They chronically dilute it!
You mean the HOPE trial? Yes they just filed to dilute further. I'm going to have to dig into management. One thing I had going in my favor with SCOR is I posted a few time their CEO/ owner and he was old. In a good way but old. And with another holding i have OPK it's the same set up.. and I could even argue ATOS... bunch of old guys who need to get out. I would love to back test this stocks with 80 year old plus owner CEO/s how do they do? I would bet fairly well. I'm sure the Foam gals are young...
Q1-2021 was Evofem's second full quarter of product sales, totaling $1.1 million. This followed the U.S. commercial launch of Phexxi on September 8, 2020. Would it be crazy to see sales at $5 mil.... They are going all out--> marketing costs were $30.5 million Think how mad you would be as an investor.. For investors, the company had sold $25 million of unsecured convertible promissory notes to Adjuvant Capital back in October 2020. The notes are convertible into shares of Evofem common stock at a conversion price of $3.65 per share, with proceeds from the sale to be used to support EVOGUARD and expand global market access for Phexxi gel. Additionally, in April, Evofem raised $4.2 million in net proceeds.<-- That's a good deal! Then, there was yet another $50 million public offering on May 17, with the shares plummeting by 35.7% the next day. -- just five days earlier (on May 12) the U.S. Food and Drug Administration (FDA) granted fast track designation to EVO100.<--- That's what we are awaiting the Trial for... 10.1%stake by Morgan Stanley (MS), Evofem Are they still in? with no FDA-approved prescription products to preventgonorrhea, a sexually transmissible disease, there is significant opportunity for Evofem, as according to anew reportpublished by the Centers for Disease Control and Prevention, more than 600,000 cases of gonorrhea were reported in 2019, representing an increase for the sixth consecutive year. Yup Young & Fun... Saundra Pelletier CEO / President Saundra Pelletier is the Chief Executive Officer, President and Executive Director of Evofem Biosciences, Inc. --multiple equity financing rounds that have raised in excess of $245 million. It is her vision and the Company’s mission to address the unmet sexual and reproductive health needs of women. Jay File- Common' It's just a hug Chief Financial Officer Jay File serves as theChief Financial Officerof Evofem Biosciences. Kelly Culwell- I'm not scary! Chief Medical Officer Kelly Culwell serves as theChief Medical Officerof Evofem Biosciences.
Lets watch this from yesterday-- OPGN. Here we do have a co going from under 1 mil a QTR so $4 mil to 7.7 mil! <---- On August 3, OPGN announced that its subsidiary, Curetis GmbH, and its instrument development and engineering partner have successfully achieved key development milestones in its Unyvero A30 RQ platform program. This should allow the company to expand its product portfolio as well as engage in strategic partnering and licensing discussions to leverage and monetize the A30 RQ platform. OPGN’s total revenue increased 34.5% year-over-year to $0.83 million in its fiscal first quarter, ended March 31. Its product sales increased 67.3% from the year-ago value to $0.61 million. Analysts expect OPGN’s revenues to increase 84.9% year-over-year to $7.79 million in the current year. The company’s EPS is expected to improve 46.8% in the current year versus the last year. Shares of OPGN have gained 9.1% over the past five days and 17.7% year-to-date. OpGen, Inc. (OPGN)- Should be $4 but It's $2.50<------ NasdaqGS - NasdaqGS Real Time Price. Currency in USD 2.4700+0.1100 (+4.66%) As of 12:
Electric Last Mile Solutions, Inc. (ELMS) 9.56+0.55 (+6.10%)<------- As of 12:25PM EDT. Matterport, Inc. (MTTR) 15.55+1.15 (+7.95%)<------- As of 12:26PM EDT. Clene Inc. (CLNN) 9.17+0.37 (+4.20%)<-------- SECTOR ALERT*** ALL OF THESE ARE SPACS COULD IT BE THE BOTTOM? IF DKNG HITS IT OUT OF THE PARK AND ROARS AHEAD $12 TOMORROW IT WILL OFFICIALLY MARK THE END OF THIS BRUTAL TRAIL OF TEARS....!!!